Quick Answer
PDS Biotechnology Corp reported Diluted EPS of $0.74 per share (loss) for fiscal year 2025.
PDS Biotechnology Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.74 | +28.2% |
| 2024 | -$1.03 | +25.9% |
| 2023 | -$1.39 | +2.8% |
| 2022 | -$1.43 | -116.7% |
| 2021 | -$0.66 | +25.8% |
| 2020 | -$0.89 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.19 | +34.5% | +9.5% |
| June 30, 2025 | -$0.21 | +8.7% | +0.0% |
| March 31, 2025 | -$0.21 | +30.0% | +27.6% |
| September 30, 2024 | -$0.29 | +17.1% | -26.1% |
| June 30, 2024 | -$0.23 | +37.8% | +23.3% |
| March 31, 2024 | -$0.30 | +6.3% | +14.3% |
| September 30, 2023 | -$0.35 | -34.6% | +5.4% |
| June 30, 2023 | -$0.37 | -85.0% | -15.6% |
- PDS Biotechnology Corp showed an increase of +28.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, PDS Biotechnology Corp’s diluted eps has grown by 16.9% (from $0.89 per share (loss) to $0.74 per share (loss)).
- The most recent figure is from PDS Biotechnology Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: